YERXA BENJAMIN R 4

What Happened
Benjamin R. Yerxa, President and Director of Opus Genetics (ticker: IRD), was granted 400,000 restricted stock units (RSUs) on January 22, 2026. The grant shows an acquisition price of $0.00 (typical for RSU awards); no immediate cash changed hands. The award vests in substantially equal quarterly installments over the next sixteen (16) quarters, subject to Yerxa’s continued service.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (filed 4 days after the transaction; appears later than the typical 2-business-day filing window).
• Transaction type/code: Grant/Award (A).
• Shares/units granted: 400,000 RSUs; acquisition price reported as $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting: Vests in substantially equal quarterly installments over 16 quarters (four years), subject to continued service (per footnote).
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in the filing.

Context
RSU grants are a common form of executive compensation and represent a future right to company stock if vesting conditions are met; they do not necessarily signal an immediate bullish market action because the recipient typically must remain employed to receive shares. The filing date suggests the Form 4 was submitted a few days after the grant date, which may be outside the usual 2-business-day reporting window for insiders.